Pds biotech versatile-002 phase 2 clinical trial meets primary study endpoints in first line recurrent/metastatic hpv16-positive head and neck cancer

30 month median overall survival (os); median os independent of patient cps score orr 34% (cps≥1); 48% (cps≥20) phase 3 registrational trial planned to initiate in 2024 princeton, n.j., may 09, 2024 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (“pds biotech” or the “company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, hosted a key opinion leader event on may 8, 2024 during which prominent experts in head and neck squamous cell cancer (“hnscc”) discussed positive, updated versatile-002 data and the unmet need in hpv16-positive hnscc.
PDSB Ratings Summary
PDSB Quant Ranking